- The expansion includes two new manufacturing suites and supporting infrastructure.
- It supports companies entering clinical development and enhances flexibility for clinical and commercial supply.
- The expansion increases process, analytical development, and quality control capacity.
- Stefan Egli, Vice President, Head of Bioconjugates, commented on the new suites.
Expansion Overview
Lonza has completed the planned expansion of its bioconjugation facility in Visp, Switzerland. The expansion includes two new manufacturing suites and supporting infrastructure, aimed at enhancing the company's capabilities and flexibility to support both clinical and commercial supply. This development is expected to meet the growing market demand for bioconjugates.
Enhanced Capabilities
The new suites complement Lonza’s recent investments in Visp, which include expansions in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These investments provide a flexible solution for customers of all sizes at a single location, helping them navigate the complexities of the bioconjugation supply chain.
Increased Capacity
In addition to the new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity. This enhancement is designed to support future portfolio growth and ensure that Lonza can meet the evolving needs of its customers.
Leadership Commentary
Stefan Egli, Vice President, Head of Bioconjugates at Lonza, stated that the opening of the new bioconjugate manufacturing suites reflects the company's dedication to continuously improving its offerings and expertise in line with market and customer needs. He emphasized that Lonza’s bioconjugation services can support projects from early phase through to late-stage and commercial programs.
